BRE 277 DDU - SNDX-275-0130
A PHASE 1 TWO-COHORT OPEN-LABEL DRUG-DRUG INTERACTION STUDY OF ENTINOSTAT AND EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH LOCALLY RECURRENT OR METASTATIC ER+ BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HEMREF 44 DDU - INCB 53914-101
A PHASE 1/2 STUDY OF INCB053914 IN SUBJECTS WITH ADVANCED MALIGNANCIES
Cancer types: Lymphoma/Leukemia, Myelofibrosis, Myeloma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HEMREF 46 DDU - eFT508-0002
A PHASE 1-2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF ORAL EFT508 IN SUBJECTS WITH HEMATOLOGICAL MALIGNANCIES
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 314 DDU - REFMAL 314
A PHASE IB DOSE-ESCALATION STUDY OF LCL161 IN COMBINATION WITH ORAL TOPOTECAN FOR PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG (SCLC) AND SELECT GYNECOLOGIC MALIGNANCIES
Cancer types: GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 320 DDU - CX-839-001
A PHASE 1 STUDY OF THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING ORAL DOSES OF THE GLUTAMINASE INHIBITOR CB-839 AS A SINGLE AGENT AND IN COMBINATION WITH STANDARD CHEMOTHERAPY IN PATIENTS WITH ADVANCED AND/OR TREATMENT-REFRACTORY SOLID TUMORS.
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 384 DDU - D6010C00005
A PHASE IB STUDY OF AZD1775 AND OLAPARIB IN PATIENTS WITH REFRACTORY SOLID TUMOURS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor, BRCA mutated
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 416 DDU - DS760C00001
A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS IMMUNOGENICITY AND ANTITUMOR ACTIVITY OF MED4276 IN SUBJECTS WITH SELECT HER2-EXPRESSING ADVANCED SOLID TUMORS
Cancer types: Breast HER2+, Gastric, Her 2 neu mutation
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 445 DDU - ISF-MC-JSCC
A PHASE 1/1B TRIAL INVESTIGATING THE CSF-1R INHIBITOR LY3022855 IN COMBINATION WITH DURVALUMAB OR TREMELIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 449 DDU - CK-101-101
A PHASE 1/2 OPEN LABEL SAFETY PHARMACOKINETIC AND EFFICACY STUDY OF ASCENDING DOSES OF ORAL CK-101 IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Colorectal, Lung NCSLC Non-Squamous, Pancreas/Biliary
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
REFMAL 452 DDU - 4020-01-001
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022 AN ANTI-TIM-3 MONOCLONAL ANTIBODY IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 460 DDU - CA-170-101
A PHASE 1 OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION TRIAL EVALUATING THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL EFFECTS OF ORALLY ADMINISTERED CA-170 IN PATIENTS WITH ADVANCED TUMORS AND LYMPHOMAS
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 463 DDU - I8S-MC-JUAB
A PHASE 1 STUDY OF A ERK1/2 INHIBITOR (LY3214996) ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED CANCER
Cancer types: Bladder, Colorectal, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, RAS mutation
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 470 DDU - BTP-114-001
A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF INTRAVENOUS ADMINISTRATION OF SINGLE AGENT BTP-114 IN PATIENTS WITH ADVANCED SOLID TUMORS AND A KNOWN DELETERIOUS BRCA OR DNA REPAIR MUTATION
Cancer types: Bladder, Breast Triple Negative, GYN, BRCA mutated
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 476 DDU - LYC-55716-1001
A PHASE 1/2A MULTICENTER OPEN-LABEL STUDY OF LYC-55716 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC CANCER
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 257 - REP0114
A RANDOMIZED PHASE 2 STUDY OF PACLITAXEL IN COMBINATION WITH REPARIXIN COMPARED TO PACLITAXEL ALONE AS FRONT-LINE THERAPY FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 260 - CP-MGAH22-04
A PHASE 3 RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS. TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT
Cancer types: Breast ER+, Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 270 - SPI-GCF-301
RANDOMIZED TRIAL OF SPI-2012 VERSUS PEGIFLGRASTIM IN THE MANAGEMENT OF CHEMOTHERAPY INDUCED NEUTROPENIA IN BREAST CANCER PATIENTS RECEIVING DOCETAXEL AND CYCLOPHOSPHAMIDE (TC) (ADVANCE-1)
Cancer types: Breast ER+, Breast HER2+, Breast Triple Negative
Lines of therapy: Neo-Adjuvant, Adjuvant

BRE 271 - ONT-380-206
PHASE 2 RANDOMIZED DOUBLE-BLINDED CONTROLLED STUDY OF ONT-380 VS. PLACEBO IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CARCINOMA
Cancer types: Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
**BRE 272 - I3Y-MC-JPBZ**
A PHASE 2 RANDOMIZED MULTICENTER 3-ARM OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB PLUS FULVESTRANT AND ABEMACICLIB PLUS TRASTUZUMAB TO STANDARD OF CARE SINGLE AGENT CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB WITH RESPECT TO PROGRESSION FREE SURVIVAL IN PATIENTS WITH HR+ HER2+ METASTATIC BREAST CANCER.

- **Cancer types:** Breast ER+, Breast HER2+
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**BRE 274 - I4O-VT-464-CL-006**
A PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF SEVITERONEL IN SUBJECTS WITH ADVANCED BREAST CANCER.

- **Cancer types:** Breast ER+, Breast Triple Negative
- **Lines of therapy:** 2nd Line Metastatic

**BRE 286 Pending - G5-US-350-1937**
A PHASE 1B STUDY FOLLOWED BY AN OPEN LABEL PARALLEL RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY TOLERABILITY AND EFFICACY OF GS-5829 IN COMBINATION WITH EXEMESTANE OR FULVESTRANT COMPARING WITH EXEMESTANE OR FULVESTRANT ALONE IN SUBJECTS WITH ADVANCED ESTROGEN RECEPTOR POSITIVE HER2- BREAST CANCER

- **Cancer types:**
- **Lines of therapy:**

**BRE 288 - G1T28-04**
PHASE 2 STUDY OF THE SAFETY EFFICACY AND PHARMACOKINETICS OF G1T28 IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER RECEIVING GEMCITABINE AND CARBOPLATIN CHEMOTHERAPY

- **Cancer types:** Breast Triple Negative
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

**CLL 31 - IPI-145-12**
A STUDY OF IPI-145 AND OFATUMUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY ENROLLED IN STUDY IPI-145-07 (CLL 30 ROLLOVER STUDY)

- **Cancer types:** Lymphoma/Leukemia
- **Lines of therapy:** Other

**CLL 39 - UTX-TGR-204**
A MULTI-CENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF UBLITUXIMAB (TG-1101) IN COMBINATION WITH TGR-1202 FOR PATIENTS PREVIOUSLY ENROLLED IN PROTOCOL UTX-TGR-304

- **Cancer types:** Lymphoma/Leukemia
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 201 - GI 201**
A PHASE II STUDY OF NAB-PACLITAXEL PLUS RAMUCIRUMAB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC GASTROESOPHAGEAL CANCER

- **Cancer types:** Esophageal, Gastric
- **Lines of therapy:** 2nd Line Metastatic

**GI 230 - MK-3475-177-00**
A PHASE III STUDY OF PEMBROLIZUMAB VS CHEMOTHERAPY IN MICROSATELLITE INSTABILITY- HIGH OR MISMATCH REPAIR DEFICIENT STAGE IV COLORECTAL CARCINOMA

- **Cancer types:** Colorectal
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GI 234 - I3O-MC-JSBF**
RANDOMIZED DOUBLE-BLIND PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS GEMCITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER

- **Cancer types:** Pancreas/Biliary
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced
GI 238 - CA209577
A RANDOMIZED MULTICENTER DOUBLE BLIND PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal
Lines of therapy: Adjuvant

GI 241 - CA209649
A RANDOMIZED MULTICENTER OPEN LABEL PHASE 3 STUDY OF NIVOLUMAB PLUS ILIUMAB OR NIVOLUMAB IN COMBINATION WITH OXALIPLATIN PLUS FLUOROPYRIMIDINE VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 1st Line Metastatic, Locally Advanced

GI 245 Pending - ISB-MC-JGDP
A PHASE 1B (OPEN-LABEL) / PHASE 2 (RANDOMIZED DOUBLE-BLINDED) STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy:

GI 247 - CanStem303C
A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC)
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic

GU 115 - I6A-MC-CBBD
A DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE/MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: Other

GU 124 - GU 124
A PHASE II STUDY OF NANOPIERCE ALBUMIN-BOUND PACLITAXEL PLUS GEMCITABINE AS FIRST-LINE THERAPY FOR THE TREATMENT OF CISPLATIN-INELIGIBLE OR CISPLATIN-INCURABLE ADVANCED UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic, Locally Advanced

GU 128 - C31005
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-AGENT MLN0128 AND COMBINATION OF MLN0128+MLN117 COMPARED WITH EVEROLIMUS IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED CLEAR-CELL RENAL CELL CARCINOMA THAT HAS PROGRESSSED ON VASCULAR ENDOTHELIAL GROWTH FACTOR-TARGETED THERAPY
Cancer types: Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line Metastatic

GU 134 - WO30070
A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPlatin VERSUS GEMCITABINE/CARBOPlatin ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic, Locally Advanced
GU 135 - MK-3475-361-00
A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 136 - CA209-920
PHASE IIIB/IV SAFETY TRIAL OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RCC
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 144 Pending - D5082c00003
A PHASE III OPEN LABEL RANDOMISED CONTROLLED MULTI-CENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF SAVOLTINIB VERSUS SUNITINIB IN PATIENTS WITH MET-DRIVEN UNRESECTABLE/LOCALLY ADVANCED OR METASTATIC PAPILLARY RENAL CELL CARCINOMA (PRCC)
Cancer types: Renal Cell
Lines of therapy: Other

GYN 51 Pending - CL-PTL-119
DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FANG TM (ADJUVANT BI-SHRNAFURIN AND GMCSF AUGMENTED AUTOLOGOUS TUMOR CELL IMMUNOTHERAPY) FOR HIGH RISK STAGE III/IV OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Adjuvant

GYN 53 Pending - PR-30-5020-C
A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED RELAPSED HIGH-GRADE SEROUS EPITHELIAL OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO HAVE RECEIVED THREE OR FOUR PREVIOUS CHEMOTHERAPY REGIMENS
Cancer types: GYN
Lines of therapy: Other

GYN 57 - C31004
A PHASE 2 RANDOMIZED STUDY OF MLN0128 (A DUAL TORC1/2 INHIBITOR) MLN0128 + MLN1117 (A PI3K? INHIBITOR) WEEKLY PACLITAXEL OR THE COMBINATION OF WEEKLY PACLITAXEL AND MLN0128 IN WOMEN WITH ADVANCED RECURRENT OR PERSISTENT ENDOMETRIAL CANCER
Cancer types: GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GYN 66 - DB488C00001
A SINGLE ARM PHASE II study to assess the efficacy and safety of the combination of CEDRANIB and OLAPARIB in women with recurrent platinum resistant ovarian fallopian tube or primary peritoneal cancer
Cancer types: GYN
Lines of therapy: 3rd Line+ Metastatic

GYN 70 - SNX-275-0603
A RANDOMIZED PLACEBO-CONTROLLED DOUBLE BLIND MULTICENTER PHASE 1B/2 STUDY OF AVELUMAB WITH OR WITHOUT ENTINOSTAT IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHICH HAS PROGRESSED OR RECURRED AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND AT LEAST TWO SUBSEQUENT LINES OF TREATMENT WITH A SAFETY LEAD-IN [SNX-275-0603]
Cancer types: GYN
Lines of therapy: Other

GYN 72 - FRV-004
A RANDOMIZED MULTICENTER PHASE II TRIAL TO EVALUATE THE SAFETY EFFICACY AND IMMUNOGENICITY OF VACCINATION WITH FOLATE RECEPTOR ALPHA PEPTIDES ADMIXED WITH GM-CSF AS A VACCINE ADJUVANT VERSUS GM-CSF ALONE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Adjuvant

Created on 10/17/2017 at 4:41 AM
BRE 253 DDU - D2270C00020
A PHASE III MULTICENTER STUDY OF THE COMBINATION OF AZD2014 AND PALBOCICLIB ON A BACKGROUND OF HORMONAL THERAPY IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER COMPRISING A SAFETY PHARMACOKINETIC AND PRELIMINARY EFFICACY EVALUATION FOLLOWED BY A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED PARALLEL GROUP EXTENSION (PASTOR)

Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HEMREF 35 DDU - 13-601
A PHASE I OPEN-LABEL MULTI-DOSE DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL NON HODGKIN LYMPHOMA (NH-L)

Cancer types: Lymphoma/Leukemia, PTCL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 108 DDU - GO29687
AN OPEN-LABEL MULTICENTER PHASE I/IB DOSE ESCALATION STUDY EVALUATING THE PHARMACOKINETICS SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF DCCS0780A ALONE OR IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA

Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 05 DDU - RXDX-101-02
AN OPEN-LABEL MULTICENTER GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOUR NTRK1/2/3 ROS1 OR ALK GENE REARRANGEMENTS

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, NTRK or ROS mutations
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 275 DDU - PMT4979g/GO000886
AN OPEN-LABEL PHASE I DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC 0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE-POSITIVE BREAST CANCER

Cancer types: Bladder, Breast Triple Negative, Gastric, GYN, Head & Neck, PI3K mutated
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 328 DDU - C34001
AN OPEN LABEL DOSE ESCALATION PHASE 1 FIRST IN HUMAN STUDY OF TAK 659 IN ADULT PATIENTS WITH ADVANCED SOLID TUMOR AND LYMPHOMA MALIGNANCIES

Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 351 DDU - IAD-MC-JTJF
A PHASE 1B TRIAL OF LY2606368 IN COMBINATION WITH EITHER CISPLATIN OR CETUXIMAB IN ADVANCED OR METASTATIC TUMORS

Cancer types: Breast ER+, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Solid Tumor, PI3K mutated
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 360 DDU - MGCD516-001
A PHASE 1/1B STUDY OF MGCD516 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, KIT,FLT3,RET,PDGFR,TRK,CBL,DDR2,KDR mutations
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 367 DDU - ALRN-6924-1-01
A PHASE I/II OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF ALRN-6924 IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING WILD-TYPE P53 PROTEIN

Cancer types: PTCL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

Created on 10/17/2017 at 4:41 AM
REFMAL 376 DDU - INCB 24360-203
A PHASE 1/2 STUDY EXPLORING THE SAFETY TOLERABILITY AND EFFICACY OF INCB024360 IN COMBINATION WITH MEDI4736 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS
Cancer types: Bladder, Head & Neck
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 390 DDU - D6130C00001
A PHASE I OPEN-LABEL MULTICENTRE DOSE ESCALATION STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AZD2811 IN PATIENTS WITH ADVANCED SOLID TUMOURS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 407 DDU - 2015-012-00US1
A MULTI-CENTER OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS OF SULFATINIB IN ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 412 DDU - D6015C00002
A PHASE I STUDY ASSESSING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AZD1775 IN COMBINATION WITH MEDI4736 IN PATIENTS WITH ADVANCED SOLID TUMOURS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 415 DDU - eFT508-0001
A PHASE 1-2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF ORAL EFT508 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 430 DDU - STML-801-0115
A PHASE 1 STUDY OF SL-801 A REVERSIBLE INHIBITOR OF NUCLEAR EXPORT IN PATIENTS WITH ADVANCED SOLID TUMOURS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 434 DDU - B9991004
A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 435 DDU - D8730C00001
PHASE 1 MONOTHERAPY MULTIPLE ASCENDING DOSE AND COMBINATION SAFETY AND TOLERABILITY STUDY OF AZD4635 IN PATIENTS WITH ADVANCED CANCER
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 326 - CA209-384
A DOSE FREQUENCY OPTIMIZATION TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS 480 MG EVERY 4 WEEKS IN ADVANCED OR METASTATIC NSCLC PATIENTS WHO RECEIVED 12 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced, Other
LYM 115 - BGB-3111-GA-101
PHASE 1B STUDY TO ASSESS SAFETY, TOLERABILITY AND ANTITUMOR ACTIVITY OF THE COMBINATION OF BGB-3111 WITH OBINUTUZUMAB IN SUBJECTS WITH B-CELL LYMPHOID MALIGNANCIES
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

LYM 118 - MK-3475-204
STUDY OF PEMBROLIZUMAB (MK-3475) VS. BRENTUXIMAB VEDOTIN IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 308 - GO29527
A PHASE III, OPEN LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PDL1 ANTIBODY) COMPARED WITH STANDARD OF CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1 SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: Adjuvant

LYM 120 - UTX-TGR-205
A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN'S LYMPHOMA.
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

LYM 126 - PCYC-1141-CA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH RITUXIMAB IN TREATMENT NAIVE SUBJECTS WITH FOLLICULAR LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

MM 75 Pending - CA209-602
AN OPEN-LABEL, RANDOMIZED PHASE 3 TRIAL OF COMBINATIONS OF NIVOLUMAB, ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Cancer types: Myeloma
Lines of therapy: 3rd Line+ Metastatic

LUN 313 - 265-109
AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY OF MGCD265 IN PATIENTS WITH RECURRENT OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) WITH SELECTED ACTIVATING GENETIC ALTERATIONS IN MESENCHYMAL-EPITHELIAL TRANSITION FACTOR (MET)
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 319 - CA209-370
A MASTER PROTOCOL OF PHASE 1/2 STUDIES OF NIVOLUMAB IN ADVANCED NSCLC USING NIVOLUMAB AS MAINTENANCE AFTER INDUCTION CHEMOTHERAPY OR AS FIRST-LINE TREATMENT ALONE OR IN COMBINATION WITH STANDARD OF CARE THERAPIES
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

MM 78 - CC-4047-MM-014
PHASE 2 STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA FOLLOWING LENALIDOMIDE-BASED THERAPY IN THE FIRST OR SECOND LINE SETTING
Cancer types: Myeloma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic


**LUN 304 - G1T28-03**

**PHASE 1B/2A SAFETY AND PHARMACOKINETIC STUDY OF G1T28 IN PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC) RECEIVING TOPOTECAN CHEMOTHERAPY**

**Cancer types:** Lung Small Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 305 - D5164C00001**

**PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291/PLACEBO IN PATIENTS WITH EGFR MUTATION POSITIVE STAGE IB-IIIA NSCLC FOLLOWING COMPLETE TUMOR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY**

**Cancer types:** Lung NCSLC Non-Squamous

**Lines of therapy:** Adjuvant

**MEL 47 - CDX011-05**

**A PHASE II STUDY OF GLEMBATUMUMAB VEDOTIN, AN ANTI-GPNMB ANTIBODY-DRUG CONJUGATE, AS MONOTHERAPY OR IN COMBINATION WITH VARLILUMAB IN PATIENTS WITH ADVANCED MELANOMA**

**Cancer types:** Melanoma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MM 74 - NSMM-5001**

**AN OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PARTICIPANTS**

**Cancer types:** Myeloma

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

**MULTI 12 - CA209-627**

**AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES**

**Cancer types:** Gastrointestinal, GYN, Solid Tumor

**Lines of therapy:** 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

**PRO 02 - ML28997**

**PHASE 2A STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS**

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**PRO 10 - PRO 10**

**STUDY TO ASSESS THE ACTIVITY OF MOLECULARLY MATCHED TARGETED THERAPIES (REGORAFENIB OR AFATINIB) IN SELECT TUMOR TYPES BASED ON GENOMIC ALTERATIONS**

**Cancer types:** Bladder, Esophageal, Gastric, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic

**REFMAL 383 - D6015C00001**

**A PHASE IB, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF AZD1775 MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMOURS**

**Cancer types:** Breast Triple Negative, GYN, Lung Small Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 140 DDU - D9320C00001**

**A PHASE 1/1B MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF MEDI0726 IN SUBJECTS WITH METASTATIC CSTRATION RESISTANT PROSTATE CANCER (mCRPC) WHO HAVE RECEIVED PRIOR TREATMENT WITH AIBRATERONE OR ENZALUTAMIDE**

**Cancer types:** Prostate

**Lines of therapy:** 3rd Line+ Metastatic
GYN 68 DDU - VS-6063-107
A PHASE 1/1B STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY CLINICAL ACTIVITY OF DEFACTINIB IN COMBINATION WITH AVELUMAB IN EPITHELIAL OVARIAN CANCER
Cancer types: GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HEMREF 50 DDU - 1101-HEM-101
A PHASE 1 DOSE ESCALATION, MULTICENTER, OPEN LABEL, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF FT-1101 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Cancer types: Hematology/Other, Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 294 DDU - GS-US-296-0101
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GS-5745 AS MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN SUBJECTS WITH ADVANCED SOLID TUMORS
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 406 DDU - D566OC00004
A PHASE 1B/2, OPEN-LABEL, MULTICENTER STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF MEDI4736 IN COMBINATION WITH AZD9150 OR AZD5069 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND SUBSEQUENTLY COMPARING AZD9150 AND AZD5069 BOTH ALONE AND IN COMBINATION WITH MEDI4736 AS SECOND-LINE TREATMENT IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 473 DDU - 1381.1
AN OPEN-LABEL, PHASE I TRIAL TO DETERMINE THE MAXIMUM TOLERATED DOSE AND INVESTIGATE SAFETY, PHARMACOKINETICS AND EFFICACY OF BI 754091 IN PATIENTS WITH ADVANCED SOLID TUMORS.
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 283 - 15-102-14
A PHASE 3 RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIANS CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE
Cancer types: Breast ER+, Breast HER2+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

PBCI Legacy Tri - M12-914
A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CARBOPLATIN AND PACLITAXEL WITH OR WITHOUT VELIPARIB (ABT-888) IN HER2-NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA-ASSOCIATED BREAST CANCER
Cancer types: Breast Triple Negative, BRCA mutated
Lines of therapy: 2nd Line Metastatic

GU 139 - CO39385
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN
Cancer types: Prostate
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

GYN 49 - D6010C00004
A MULTICENTRE RANDOMISED PHASE II STUDY OF AZD1775 PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH PLATINUM-RESISTANT TP53- MUTATED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Cancer types: GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
**LUN 338 - I4T-MC-JVDL**

An open-label, multicenter, Phase 1 study with expansion cohorts of ramucirumab or necitumumab in combination with osimertinib in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer after progression on first-line EGFR TKI therapy.

Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous

Lines of therapy: Other

**REFMAL 484 DDU - D8360C00001**

A phase I, open-label, multicentre dose-escalation study to investigate the safety and pharmacokinetics of AZD4785 in patients with advanced solid tumours where KRAS may be an important driver of tumour survival.

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, RAS mutation

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

**LYM 122 - ACE-LY-308**

A phase 3, randomized, double-blind, placebo controlled, multicenter study of BR alone versus in combination with acalabrutinib (ACP-196) in subjects with previously untreated mantle cell lymphoma.

Cancer types: Lymphoma/Leukemia

Lines of therapy: 1st Line Metastatic - Locally Advanced

**MM 66 Pending - CA204142**

A phase 2, multiple cohort study of elotuzumab in combination with pomalidomide and low-dose dexamethasone (EPD), and in combination with nivolumab (EN), in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide.

Cancer types: Bladder, Myeloma

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

**MPN 09 - PAC203**

An open-label, randomized, Phase 2 dose-finding study of pacritinib in patients with primary myelofibrosis previously treated with ruxolitinib.

Cancer types: Myelofibrosis

Lines of therapy: 2nd Line Metastatic

**REFMAL 495 DDU - D6520C00001**

A Phase I, multicenter dose-escalation study to assess the tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD5153 in patients with relapsed/refractory malignant solid tumors, including lymphomas.

Cancer types: Bladder, Breast ER+, Breast Triple Negative, Colorectal, GYN, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Prostate, Solid Tumor

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 355 DDU - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL E**

RXDX-101-01

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor, NTRK or ROS mutations

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 485 DDU - 1381.2**

An open-label, phase I dose-finding study of BI 754111 as monotherapy and in combination with BI 754091 in patients with advanced cancer followed by expansion cohorts at the RP2D of the combination in patients with NSCLC and other tumour types.

Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Renal Cell

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

**CLL 41 - TGR-1202-201**

Evaluate the efficacy and safety of TGR-1202 in patients with chronic lymphocytic leukemia who are intolerant to prior therapy.

Cancer types: Lymphoma/Leukemia

Lines of therapy: 2nd Line Metastatic
GU 147 - WO39210
A STUDY OF ATEZOLIZUMAB AS ADJUVANT THERAPY IN PARTICIPANTS WITH RENAL CELL CARCINOMA (RCC) AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY (IMMOTION010)
Cancer types: Renal Cell
Lines of therapy: Adjuvant

REFMAL 520 DDU - CP-MGD013-01
A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION STUDY OF MGD013, A DUAL-AFFINITY RE-TARGETING (DART®) PROTEIN BINDING PD-1 AND LAG-3 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS
Cancer types: Bladder, Breast Triple Negative, Gastric, GYN, Head & Neck, Liver Liver NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell, MSI High
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MEL 54 - CO39262
A STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PARTICIPANTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
Cancer types: Melanoma
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 350 - B7461006
A STUDY OF LORLATINIB VERSUS CRIZOTINIB IN FIRST LINE TREATMENT OF PATIENTS WITH ALK-POSITIVE NSCLC
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 142 - CO-338-052
A STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION GENE DEFICIENCY
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 361 Pending - GH03-001
NONINVASIVE VS. INVASIVE LUNG EVALUATION (NILE-TRIAL)
Cancer types: Lung NCSLC Non-Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 294 - CLEE011G2301
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF RIBOCICLIB WITH ENDOCRINE THERAPY AS AN ADJUVANT TREATMENT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, HIGH RISK EARLY BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant

LUN 358 Pending - D419MC00004
THIS IS A PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE GLOBAL PHASE 3 STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF DURVALUMAB OR DURVALUMAB + TREMELUMAB IN COMBINATION THERAPY WITH PLATINUM BASED CHEMOTHERAPY FOR THE FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC).
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced
MULTI 25 Pendin - D4191C00068
AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) – CORE PROTOCOL

Cancer types: Bladder
Lines of therapy: 2nd Line Metastatic

GYN 63 - PRO-105
A PHASE II OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF ACELARIN® (NUC-1031) GIVEN ON DAYS 1, 8 AND 15 OF A 28-DAY SCHEDULE IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

Cancer types: GYN
Lines of therapy: 3rd Line+ Metastatic

LYM 132 - INCB 50465-203
AN OPEN-LABEL, RANDOMIZED STUDY COMPARING INCB050465 TO IDELALISIB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Cancer types: Lymphoma/Leukemia
Lines of therapy: 3rd Line+ Metastatic